3 recruiting. 3 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Recruiting 3 |
| Phase 2 | 2 | Recruiting 2 |
Follow Anorexia: new trials by email Literature Review of Anorexia trials Research Report on Anorexia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma Nanocrystalline Megestrol Acetate Oral Suspension, Placebo - Nasopharyngeal Cancinoma (NPC) | Phase 3 | Recruiting | Sun Yat-sen University | 204 | 2026-09-29 | 2026-10-15 |
| Visugromab in Cachexia International Trial Visugromab (CTL-002), Placebo - Cancer-associated Cachexia | Phase 2 / Phase 3 | Recruiting | CatalYm GmbH | 518 | 2026-04-16 | 2026-11-02 |
| A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue ponsegromab, placebo - Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | Pfizer | 982 | 2025-10-03 | 2026-10-14 |
Weight Loss (3) · Cachexia (2) · Neoplasms (2) · Fatigue (1) · Nasopharyngeal Carcinoma (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1)
Body Weight (3) · Body Weight Changes (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Signs and Symptoms, Digestive (3) · Neoplasms by Site (2) · Thinness (2) · Carcinoma (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Head and Neck Neoplasms (1) · Nasopharyngeal Diseases (1) · Nasopharyngeal Neoplasms (1)
CatalYm GmbH (1) · Pfizer (1) · Sun Yat-sen University (1)
Bulgaria (2) · China (2) · France (2) · Germany (2) · Italy (2) · Poland (2) · Spain (2) · United Kingdom (2) · United States (2) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · Czechia (1) · India (1)
2025 (1)